Strengthened70% impact weight
The contested handling and suspension of the Dengvaxia program is widely cited as a major boost to vaccine hesitancy and distrust of immunization in the Philippines. Causal magnitude is debated, hence medium confidence.
actionverifiedconfidence: high
Philippines suspends Dengvaxia dengue-vaccination program after Sanofi safety warning (2017)
After the Philippine Department of Health introduced Dengvaxia in a school-based programme, Sanofi advised in November 2017 that vaccination could increase the risk of severe dengue in people without prior infection. The department suspended the programme. This record covers the documented programme and safety response without assigning individual legal culpability.
- Contributor1
- This fact
- Driver1
- Indicators2
What happened
Recorded event summary.
After the Philippine Department of Health introduced Dengvaxia in a school-based programme, Sanofi advised in November 2017 that vaccination could increase the risk of severe dengue in people without prior infection. The department suspended the programme. This record covers the documented programme and safety response without assigning individual legal culpability.
Affected drivers
Welfare indicators reached
Lower is better Higher is better
Causal network
This fact’s slice of Factrail’s verified causal web — the people, facts, drivers and welfare indicators it connects to. Select any node to trace a path.
Loading network…